The mega COMBO collaboration: An individual patient data pooled analysis of patients undergoing PCI with COMBO stent

Matteo Nardin, Carlo Andrea Pivato, Davide Cao, Samantha Sartori, Zhongjie Zhang, Birgit Vogel, Johny Nicolas, Mauro Chiarito, Hanbo Qiu, Jaya Chandrasekhar, Alessandro Spirito, Alexandre Abizaid, Evald Høj Christiansen, Antonio Colombo, Robbert J. de Winter, Michael Haude, Lars Jakobsen, Lisette Okkels Jensen, Mitchell W. Krucoff, Ulf LandmesserShigeru Saito, Harry Suryapranata, Giuseppe De Luca, George Dangas, Roxana Mehran

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Background: COMBO (OrbusNeich Medical, Hong Kong) is a dual-therapy coronary stent featuring sirolimus as antiproliferative drug and an anti-CD34+ antibody coating to attract endothelial progenitor cells favoring rapid stent re-endothelization. The Mega COMBO collaboration aimed to evaluate the performance of the COMBO stent in a large contemporary cohort of patients undergoing percutaneous coronary intervention (PCI). Methods: Patient-level data of subjects undergoing PCI with the COMBO stent from the REMEDEE-Trial, REMEDEE-OCT, HARMONEE, REDUCE, SORT OUT X, REMEDEE-Registry and MASCOT studies were pooled together. The primary endpoint was 1-year target lesion failure (TLF), a composite of cardiovascular death, target vessel myocardial infarction (TV-MI) or clinically driven target lesion revascularization (CD-TLR). Secondary outcomes were the individual components of the primary endpoint and stent thrombosis (ST). Endpoints were evaluated against performance goals based on the EAPCI (the European Association of Percutaneous Coronary Intervention) recommendations for new drug-eluting stents. Results: A total of 6753 patients (mean age 63.7 ± 11.4 years, 23% women) were included. At 1-year follow-up, TLF occurred in 303 (4.6%) patients. The rates of cardiovascular death, TV-MI, and CD-TLR were 1.3%, 1.8%, and 2.5%, respectively. The rate of definite/probable ST was 0.73%, early ST (<1 month) was 0.48%, while late ST (1–12 months) was 0.26%. The performance goals were met for all of the evaluated endpoints. Conclusions: This large patient-level pooled analysis provides a comprehensive outline of the performance of the dual-therapy COMBO stent. The low rates of primary and secondary endpoints suggest that this stent technology may be a good alternative to other contemporary drug eluting coronary stent platforms.

Original languageEnglish
Pages (from-to)149-155
Number of pages7
JournalInternational Journal of Cardiology
StatePublished - 1 Jan 2023


  • COMBO stent
  • Dual-therapy stent
  • Individual patient data analysis
  • Percutaneous coronary intervention


Dive into the research topics of 'The mega COMBO collaboration: An individual patient data pooled analysis of patients undergoing PCI with COMBO stent'. Together they form a unique fingerprint.

Cite this